1차 출처 기록
결정급탑라인 결과
AVTX-009 2상 LOTUS 시험 HS: 주요 데이터 Q2 2026 예상
Avalo가 HS에서 AVTX-009의 2상 LOTUS 시험 등록을 완료했습니다. 주요 결과는 현재 Q2 2026로 안내되며, 해당 자산의 다음 규제/임상 이정표를 확립합니다.
핵심 사실
출처 발췌
EX-99.1 2 ex-991_dec2025xavalocorp.htm EX-99.1 ex-991_dec2025xavalocorp ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW December 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation,